Procaps Group - PROC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.56
▼ -0.065 (-4.00%)

This chart shows the closing price for PROC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Procaps Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PROC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PROC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Procaps Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.56.

This chart shows the closing price for PROC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Procaps Group. This rating has held steady since September 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/6/2023Brookline Capital ManagementDowngradeBuy ➝ Hold$4.50
12/14/2021Brookline Capital AcquisitionInitiated CoverageBuy$13.00
12/14/2021Brookline Capital ManagementReiterated RatingBuy$13.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/6/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/3/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Procaps Group logo
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Read More

Today's Range

Now: $1.56
Low: $1.52
High: $1.60

50 Day Range

MA: $1.71
Low: $0.53
High: $2.24

52 Week Range

Now: $1.56
Low: $0.50
High: $4.95

Volume

12,129 shs

Average Volume

31,107 shs

Market Capitalization

N/A

P/E Ratio

3.00

Dividend Yield

N/A

Beta

0.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Procaps Group?

The following sell-side analysts have issued reports on Procaps Group in the last year:
View the latest analyst ratings for PROC.

What is the current price target for Procaps Group?

0 Wall Street analysts have set twelve-month price targets for Procaps Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Procaps Group in the next year.
View the latest price targets for PROC.

What is the current consensus analyst rating for Procaps Group?

Procaps Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PROC.

What other companies compete with Procaps Group?

How do I contact Procaps Group's investor relations team?

Procaps Group's physical mailing address is 1425 BRICKELL AVE #57B, MIAMI FL, 33131. The company's listed phone number is 356 7995-6138 and its investor relations email address is [email protected]. The official website for Procaps Group is unionacquisitiongroup.com. Learn More about contacing Procaps Group investor relations.